Document Detail

Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy.
MedLine Citation:
PMID:  9207819     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine whether ranitidine (Zantac) taken once or twice daily is effective for relieving symptoms of gastroesophageal reflux among pregnant women who had failed conservative measures. METHODS: Volunteers with heartburn despite antacids were sought among our obstetrics clinic population for this double-blind, placebo-controlled, triple crossover trial. After a baseline week, 20 patients were randomized to receive the three following weekly regimens: ranitidine 150 mg twice daily, placebo in the morning and ranitidine 150 mg in the evening, or placebo twice daily. Daily scores on symptom diaries, global assessments, and number of antacids taken were compared among the 18 patients completing the study. RESULTS: The twice-daily dosage of ranitidine was the only regimen found to reduce heartburn symptoms when compared with the baseline (P < .001) or a placebo (P < .01). Compared with ranitidine taken once daily, the twice-daily dosing prompted less need for antacid tablets compared with the placebo (P < .05 versus P > .05) and to the baseline (P < .001 versus P < .05). The average reduction of heartburn severity using twice-daily ranitidine was 55.6% when compared with baseline (95% confidence interval [CI] 34.8%, 76.5%) was 44.2% when compared with placebo (95% CI 15.4%, 72.9%). CONCLUSION: This study indicates the efficacy of ranitidine 150 mg taken twice daily, rather than once daily, for relief of gastroesophageal reflux symptoms during pregnancy.
J D Larson; E Patatanian; P B Miner; W F Rayburn; M G Robinson
Related Documents :
18347479 - Measurement of upper limb ulcers in patients with systemic sclerosis: reproducibility a...
20061959 - Impact of oesophagitis classification in evaluating healing of erosive oesophagitis aft...
8931419 - Prevention with sucralfate gel of nsaid-induced gastroduodenal damage in arthritic pati...
9395759 - Intravenous cyclosporine for severe attacks of ulcerative colitis: a survey of canadian...
7020469 - Efficacy of (e)-5-(2-bromovinyl)-2'-deoxyuridine in the topical treatment of herpes sim...
10908469 - Compression for venous leg ulcers.
7863249 - Continuous infusions of nizatidine are safe and effective in the treatment of intensive...
21515889 - Weight transfer analysis in adults with hemiplegia using ankle foot orthosis.
23723549 - Psychiatric manifestations in a patient with hiv-associated neurocognitive symptoms and...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  90     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  1997 Jul 
Date Detail:
Created Date:  1997-07-31     Completed Date:  1997-07-31     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  83-7     Citation Subset:  AIM; IM    
Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine, Oklahoma City, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cross-Over Studies
Double-Blind Method
Gastroesophageal Reflux / drug therapy*
Heartburn / drug therapy*
Histamine H2 Antagonists / therapeutic use*
Pregnancy Complications / drug therapy*
Ranitidine / therapeutic use*
Reg. No./Substance:
0/Histamine H2 Antagonists; 66357-35-5/Ranitidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Underreporting of maternal mortality in The Netherlands.
Next Document:  Absorption kinetics of misoprostol with oral or vaginal administration.